A synthetic exendin-4* and glucagon-like peptide-1–GLP-1 agonist used to manage type 2 diabetes with once-weekly injections due to its longer half-life.
*A protein isolated from the Gila monster
Mechanism of action Increases insulin secretion in response to meals, helping lower the post-prandial rise in serum glucose; suppresses pancreatic release of glucagon in response to eating; slows gastric emptying; promotes satiety by acting on hypothalamic receptors; reduces liver fat.
Adverse effects Gastric acidity, belching, diarrhoea, indigestion, nausea, vomiting
Proprietary names Bydureon®, Byetta®